(Q50569333)

English

Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin

scientific article published on 25 January 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Carroll B Leevy

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

publication date

25 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

53

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

1961-1966

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10620-007-0076-Y

21 January 2018

The role of three domains in the biological activity of human interferon-alpha

1 reference

https://api.crossref.org/works/10.1007%2FS10620-007-0076-Y

21 January 2018

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The burden of hepatitis C in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HIV and hepatitis C virus co-infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response to interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18219576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-007-0076-Y

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/18219576

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50569333&oldid=2253302163"